One-carbon metabolism in psychiatric illness
Author:
Open Access
- 1 June 2006
- journal article
- Published by Cambridge University Press (CUP) in Nutrition Research Reviews
- Vol. 19 (1) , 117-136
Abstract
The cost of psychiatric illness to the UK economy was recently estimated at £77 billion annually. Despite years of research no firm aetiological explanation exists, and with no physiological or biochemical markers diagnosis is made entirely on a behavioural basis. All current pharmacological therapies are associated with serious long-term side effects. Substantial evidence supports the involvement of one-carbon cycle dysregulation in psychiatric illness, but this is not currently used as a basis for diagnosis or treatment. The present paper reviews the evidence for one-carbon cycle dysregulation in schizophrenic, bipolar, depressed and autistic patients. Also presented are novel findings from the field of epigenetics, which demonstrate how the one-carbon cycle-derived methyl donorS-adenosylmethionine influences the expression of key genes in the brain affecting memory, learning, cognition and behaviour, genes whose expression is reduced to varying degrees in these patient groups. Clinical evidence that nutritional supplements can rectify one-carbon cycle activity, and restore normal gene expression, suggests a novel approach to the development of biochemical tests and simple, non-harmful treatments for some psychiatric patients. Conversely, evidence from animal studies highlights the dangers of exposing the unborn fetus to very high dietary levels of folic acid, a one-carbon cycle cofactor. Fetal adaptations to a high-folate environment may interfere with folate metabolism postnatally, with serious consequences for the epigenetic regulation of gene expression. The public health implications of these diverse scenarios indicate an urgent need for further research in this field.Keywords
This publication has 133 references indexed in Scilit:
- Nutritional and life style determinants of plasma homocysteine in schizophrenia patientsEuropean Neuropsychopharmacology, 2005
- Cancer in schizophrenia: is the risk higher or lower?Schizophrenia Research, 2005
- CSF homocysteine is not elevated in schizophreniaJournal of Neural Transmission, 2005
- GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellumSchizophrenia Research, 2005
- CSF-methionine is elevated in psychotic patientsJournal of Neural Transmission, 2004
- Can terathanasia explain the protective effect of folic-acid supplementation on birth defects?The Lancet, 1997
- Prevention of neural tube defects: Results of the Medical Research Council Vitamin StudyThe Lancet, 1991
- Choline deficiency activates phospholipases A2 and C in rat liver without affecting the activity of protein kinase CThe Journal of Nutritional Biochemistry, 1990
- Neuropsychiatric Disorders Caused by Cobalamin Deficiency in the Absence of Anemia or MacrocytosisNew England Journal of Medicine, 1988
- The effects of L-methionine (without MAOI) in schizophreniaJournal of Psychiatric Research, 1971